Im waiting until late 2022 until the results come out before buying in. If the phase 3 clinical trials are a flop, then the SP tanks. If the phase 3 clinical trials are positive and the drug is released into the US, the SP will obviously rocket. However, I believe it would still be worth investing following positive news, considering PAS will have 17 years before any other company can release the same/slightly modified drug. Thus, they will have market share for 17 years. Its about protecting your downside without limiting your upside. With 40 years of investing experience, its always best to be sure about the company prior to investing, and thus I will wait until late 2022.
This is my opinion only, so DYOR.
PharmD price target fun, page-63
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.5¢ |
Change
0.010(4.65%) |
Mkt cap ! $78.73M | |||
| Open | High | Low | Value | Volume |
| 22.0¢ | 23.5¢ | 21.5¢ | $288.5K | 1.279M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 130626 | 22.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.0¢ | 60000 | 1 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| PAR (ASX) Chart |